

Minutes of the Institute Biosafety Committee Meeting

July 15, 2026

Convened at: 1:00 pm and Adjourned at 1:52 pm

Present: Drs. Gelman (Chair), Ding, Fang, Gerber, Ionov, McGray, Thanavala, Mr. Hartley, Ms. Holtz, Ms Keough and Mr. Flagler.

Absent: Mr. Atwal, Ms. Herter

ORSP Staff: Ms. Pusateri, Mr. Caruana, Ms. Bennett

Guests: None

Meeting Place: Virtual meeting/Teams.

Minutes of June 10, 2026 were approved.

Vote: Unanimous.

Adverse Event/Accident/Incident Report

May Employee Health Service report; pending.

ORSP - No reports.

Old Business

1. Safety Story; this months story highlighted the air quality of wildfires, dangers to at risk groups, and how events occurring far away can impact us.
2. Laboratory inspections; February, March and May checklists complete.

New Business:

1. Lab educational visits:

3 Laboratories were visited June 11th with Dr. Ionov and Ms Bennett joining the team.

a. Fenstermaker/Ciesielski BSL2lab: OES to follow up (see checklist).

b. Takabe/Hait BSL2 lab: OES to follow up (see checklist).

c. Knudsen BSL2+ lab: OES to follow up (see checklist).

3 Laboratories were visited July 2nd with Dr McGray joining the team.

a. Bakin BSL2+ Lab: OES to follow up (see checklist).

b. Tang BSL2+ Lab: OES to follow up (see checklist).

c. Genomics Core BSL2 Lab: no follow up required.

The next inspection date will be Thursday, August 6th with Dr. Thanavala joining the team.

Protocol review:

19 Biosafety applications were reviewed. 7 were continuing reviews.

3 Protocols referenced Virus

Application for 1740M/Lab Based: Approved.

Reviewed by Dr. McGray

The 1740M/lab based application, 24-07-1609 entitled: "Testing Drug Effectiveness in Mouse and Patient Derived Models of Bladder Cancer." PI: Huss, Wendy was approved.

The purpose of this protocol is to determine the cell lineage giving rise to bladder cancer with sarcomatoid or small cell features.

Biosafety agents include: lentivirus, and compounds.

Application for 1642M/Lab Based: Approved pending.

Reviewed by Dr. Gelman

The amendment application for full committee review 25-02-1656 entitled: "Deciphering the Interplay Between Metabolism and Tumor Initiation, Growth, and Progression." PI: Wilde, Blake was approved pending designated member review of revised application.

The purpose of this protocol is to determine the role of the oncometabolite fumarate in driving renal clear cell tumor growth.

Biosafety agents include: lentivirus, AAV, and compounds.

Application for 1605M/Lab Based: Approved pending.

Reviewed by Dr. Ding

The 1605M/lab based application, 25-11-1705 entitled: "Biosafety Protocol for VSIG4 Experiments." PI: Gudkov, Andrei was approved pending designated member review of a revised application.

The purpose of this protocol is to study VSIG4 in the context of tumor microenvironment.

Biosafety agents include: lentivirus

Exempt from full committee review:

Application for 1443M/Lab Based: Approved.

Reviewed by Dr. Ionov

The application, 26-06-1745 entitled: "Photodynamic Therapy (PDT) and Sonodynamic Therapy (SDT) for the treatment of Prostate Cancer." PI: Sumlin, Adam was approved as Exempt from full committee review 7/6/2026.

Biosafety agents include: Human cell lines.

Amendments:

Application for Lab Based: Approved.

Reviewed by Dr. Thanavala

The amendment to Lab based 24-05-1600 entitled: "Gelman Lab Biosafety Application" PI: Gelman, Irwin was approved on 6/11/2026.

Biosafety agents used include: 2 new cell lines.

Application for Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based 24-07-1608 entitled: "Qiang Li Biosafety Application" PI: Li, Qiang was approved 6/11/2026.

Biosafety agents used include: 13 new cell lines.

Application for Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based 25-05-1670 entitled: "Activating Anti-MDS Immunity Through Restoration of the Immune Microenvironment" PI: Nemeth, Michael was approved 6/15/2026.

Biosafety agents used include: additional retroviral vectors and cell lines.

Application for Core: Approved.

Reviewed by Dr. Gelman

The amendment to Core 23-12-1557 entitled: "Laboratory Animal Resources Research" PI: Curtin, Leslie was approved 6/22/2026.

Biosafety agents used include: 2 human cell lines.

Application for Core: Approved.

Reviewed by Dr. Gelman

The amendment to Core 25-01-1643 entitled: "Core: Translational Imaging Shared Resource Biosafety Protocol" PI: Sperry, Joseph was approved 6/23/2026.

Biosafety agents used include: 2 human cell lines.

Application for Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based 24-02-1571 entitled: "Gurova Lab Biosafety protocol" PI: Gurova, Katerina was approved 6/26/2026.

Biosafety agents used include: updated work for other protocols; cell lines, compounds.

Application for Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based 24-03-1572 entitled: "Enhancement of PDT Using Biological Response Modifiers" PI: Shafirstein, Gal was approved 7/5/2026.

Biosafety agents used include: new compounds.

Application for Lab Based: Approved.

Reviewed by Dr. Gelman

The amendment to Lab based 26-02-1721 entitled: "Investigating Metabolic Mechanisms of Tumor Growth and Anti-Tumor Immunity" PI: Longo, Joseph was approved 7/14/2026.

Biosafety agents used include: new compounds and cell lines.

See attached for complete list.

Respectfully Submitted,



Irwin Gelman, PhD
Institute Biosafety Committee Chair
Director of Research Integration; Professor of
Oncology